Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Pliant Therapeutics, Inc.’s PLRX share price has surged by 10.39%, which has investors questioning if this is right time to sell.

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration ...

Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated ...

The Indian Institute of Science (IISc) is India's premier institute for advanced research and higher education. With over 40 departments and centres under six major divisions, the institute offers ...

This is a Phase 1 open label trial of PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to block TGF-β activation in the tumor microenvironment. The ...

Credit: Nano Letters (2025). DOI: 10.1021/acs.nanolett.4c05858 When ultrasound was applied to cancer cells grown on the 50 nm and 70 nm platforms, their cell membranes were found to stretch due to ...

Shelby is an Assistant Editor for The Scientist. She earned her PhD from West Virginia University in immunology and microbiology and completed an AAAS Mass Media fellowship. View Full Profile. Learn ...

Integrins require an activation step prior to ligand binding and signaling. How talin and kindlin contribute to these events in non-hematopoietic cells is poorly understood. Here we report that ...